Free Trial
NASDAQ:IRWD

Ironwood Pharmaceuticals Q1 2025 Earnings Report

Ironwood Pharmaceuticals logo
$1.36 -0.04 (-2.52%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ironwood Pharmaceuticals EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Ironwood Pharmaceuticals Revenue Results

Actual Revenue
$41.14 million
Expected Revenue
$67.02 million
Beat/Miss
Missed by -$25.88 million
YoY Revenue Growth
N/A

Ironwood Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Ironwood Pharmaceuticals' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ironwood Pharmaceuticals Earnings Headlines

Ironwood Pharma Regains Nasdaq Compliance
Ironwood (IRWD) Q2 EPS Jumps 600%
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Ironwood Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ:IRWD) is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S. markets under the brand name CONSTELLA.

In addition to its marketed therapy, Ironwood maintains a diversified pipeline of clinical and preclinical programs targeting GI motility, inflammation and neurological conditions. Lead pipeline candidates include novel small molecules designed to modulate gut motility and secretions, as well as agents aimed at central nervous system targets to address pain and neurodegenerative disorders. The company leverages in-house research capabilities alongside external partnerships to advance its portfolio.

Founded in 1998 as Microbia Biosciences, the business rebranded as Ironwood Pharmaceuticals in 2010 concurrent with its initial public offering. Headquartered in Cambridge, Massachusetts, Ironwood conducts research and development activities in the U.S. and collaborates with global pharmaceutical partners to extend its reach into European, Canadian and other international markets.

Ironwood is led by President and Chief Executive Officer Peter Hecht, who brings extensive experience in both commercial operations and strategic development within the biopharmaceutical industry. Under his leadership, the company continues to pursue innovative therapies aimed at addressing unmet needs in GI health and related therapeutic areas.

View Ironwood Pharmaceuticals Profile

More Earnings Resources from MarketBeat